Published in Front Microbiol on October 25, 2016
Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond B Biol Sci (2017) 0.75
The Methylation Status and Expression of Epstein-Barr Virus Early Genes BARF1 and BHRF1 in Epstein-Barr Virus-Associated Gastric Carcinomas. Gastroenterol Res Pract (2017) 0.75
An essential EBV latent antigen 3C binds Bcl6 for targeted degradation and cell proliferation. PLoS Pathog (2017) 0.75
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer (1973) 14.90
VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. Lancet (1964) 14.21
The global health burden of infection-associated cancers in the year 2002. Int J Cancer (2006) 13.57
Identification of virus-encoded microRNAs. Science (2004) 12.56
Comprehensive molecular characterization of gastric adenocarcinoma. Nature (2014) 11.93
Plasma cell differentiation requires the transcription factor XBP-1. Nature (2001) 9.72
Epstein-Barr virus: 40 years on. Nat Rev Cancer (2004) 9.70
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol (2012) 9.28
Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. Proc Natl Acad Sci U S A (1968) 8.67
Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int J Cancer (1968) 6.29
Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity (2002) 6.27
The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell (1995) 5.97
U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci U S A (1984) 5.27
Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol (2001) 5.08
Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol (2007) 4.14
Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol (1993) 4.05
Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood (2008) 3.81
Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature (2012) 3.77
Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol (1990) 3.51
Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol (1992) 3.41
The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer (2011) 3.31
Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol (2005) 3.16
Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A (2001) 2.98
The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J Virol (1998) 2.84
MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics (2010) 2.80
Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol (2006) 2.79
Epstein-Barr virus and cancer. Clin Cancer Res (2004) 2.78
Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinocytes through NF-kappaB and PPARgamma. Cell Death Differ (2002) 2.60
Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene. Trends Microbiol (1997) 2.50
Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis (2008) 2.42
Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med (1998) 2.40
Association of Epstein-Barr virus with undifferentiated gastric carcinomas with intense lymphoid infiltration. Lymphoepithelioma-like carcinoma. Am J Pathol (1991) 2.37
Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev (1997) 2.36
Mesenteric panniculitis: various presentations and treatment regimens. World J Gastroenterol (2009) 2.30
Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa. J Virol (1995) 2.25
Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev (2011) 2.22
A dynamic model for the allosteric mechanism of GroEL. J Mol Biol (2000) 2.20
Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol (2009) 2.20
Determination of the c-MYC DNA-binding site. Proc Natl Acad Sci U S A (1991) 2.19
An emerging role for epigenetic dysregulation in arsenic toxicity and carcinogenesis. Environ Health Perspect (2010) 2.16
Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer (2010) 2.06
The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). J Virol (1996) 1.97
Etiology of Burkitt's lymphoma--an alternative hypothesis to a vectored virus. J Natl Cancer Inst (1969) 1.95
Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol (2003) 1.93
Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Mol Cell (2005) 1.92
Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem (1999) 1.83
Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn (2008) 1.82
The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol (1999) 1.81
Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol (2009) 1.78
Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J Virol (2000) 1.77
The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol (1998) 1.76
Epstein-barr virus-induced changes in B-lymphocyte gene expression. J Virol (2002) 1.72
EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity (2000) 1.69
Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev (2010) 1.68
EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist (2008) 1.61
A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol Cell Biol (1995) 1.59
Dominant-negative inhibitors of EBNA-1 of Epstein-Barr virus. J Virol (1997) 1.59
Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol (1995) 1.58
Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol (2003) 1.58
Reactivation of Epstein-Barr virus from latency. Rev Med Virol (2005) 1.58
The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species. Proc Natl Acad Sci U S A (2009) 1.57
Lytic cycle switches of oncogenic human gammaherpesviruses. Adv Cancer Res (2007) 1.57
Suppression of Myc, but not E1a, transformation activity by Max-associated proteins, Mad and Mxi1. Proc Natl Acad Sci U S A (1994) 1.56
Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood (1998) 1.55
Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev (2007) 1.54
A role for SKIP in EBNA2 activation of CBF1-repressed promoters. J Virol (2000) 1.53
Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene (2005) 1.51
Epstein-Barr virus infection in ex vivo tonsil epithelial cell cultures of asymptomatic carriers. J Virol (2004) 1.48
Epstein-Barr virus nuclear protein EBNA-3C interacts with the human metastatic suppressor Nm23-H1: a molecular link to cancer metastasis. Nat Med (2001) 1.48
MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling. EMBO Rep (2002) 1.47
EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas. PLoS Pathog (2007) 1.46
Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc Natl Acad Sci U S A (2005) 1.45
Latent and lytic Epstein-Barr virus replication strategies. Rev Med Virol (2004) 1.45
Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe (2014) 1.42
Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes. J Virol (1999) 1.41
Cell cycle regulation of chromatin at an origin of DNA replication. EMBO J (2005) 1.40
Acetylation-dependent regulation of Skp2 function. Cell (2012) 1.40
HDAC1 cooperates with C/EBPalpha in the inhibition of liver proliferation in old mice. J Biol Chem (2008) 1.38
Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta 1-mediated growth inhibition in EBV-positive B cells. J Immunol (1995) 1.36
Epstein-Barr virus mRNA export factor EB2 is essential for production of infectious virus. J Virol (2002) 1.36
Targeting Hepatitis B Virus With CRISPR/Cas9. Mol Ther Nucleic Acids (2014) 1.33
Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood (2007) 1.32
Critical role of Epstein-Barr Virus (EBV)-encoded RNA in efficient EBV-induced B-lymphocyte growth transformation. J Virol (2005) 1.32
Epstein-Barr virus and nasopharyngeal carcinoma. Chin J Cancer (2014) 1.32
Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies. PLoS Pathog (2008) 1.31
Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. J Virol (2009) 1.31
MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. J Virol (2009) 1.31
Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus. J Virol (2007) 1.31
The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo. J Virol (2000) 1.30
Serological diagnosis of Epstein-Barr virus infection: Problems and solutions. World J Virol (2012) 1.26
Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Mol Pathol (2000) 1.26
Early events associated with infection of Epstein-Barr virus infection of primary B-cells. PLoS One (2009) 1.26
An immunohistological study of immunoglobulin content of primary central nervous system lymphomas. Cancer (1978) 1.25
Induction of Id1 and Id3 by latent membrane protein 1 of Epstein-Barr virus and regulation of p27/Kip and cyclin-dependent kinase 2 in rodent fibroblast transformation. J Virol (2004) 1.25
Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes. Clin Cancer Res (2011) 1.25
Signal Transduction and Transcription Factor Modification during Reactivation of Epstein-Barr Virus from Latency. J Virol (2002) 1.23
Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation. Oncogene (2005) 1.21